GSK plc (GSK)

NYSE: GSK · IEX Real-Time Price · USD
42.87
-0.12 (-0.28%)
At close: Mar 28, 2024, 4:00 PM
43.00
+0.13 (0.30%)
After-hours: Mar 28, 2024, 7:51 PM EDT
-0.28%
Market Cap 88.16B
Revenue (ttm) 38.39B
Net Income (ttm) 6.24B
Shares Out 2.03B
EPS (ttm) 3.03
PE Ratio 14.24
Forward PE 10.83
Dividend $1.62 (3.79%)
Ex-Dividend Date Feb 22, 2024
Volume 1,854,644
Open 43.00
Previous Close 42.99
Day's Range 42.86 - 43.22
52-Week Range 33.33 - 43.84
Beta 0.26
Analysts Strong Buy
Price Target 46.00 (+7.3%)
Earnings Date Apr 24, 2024

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]

Sector Healthcare
Founded 1715
Employees 70,212
Stock Exchange NYSE
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for GSK stock is "Strong Buy." The 12-month stock price forecast is $46.0, which is an increase of 7.30% from the latest price.

Price Target
$46.0
(7.30% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has regained full ownership from GSK of HTL0027477 (formerly GSK4381...

8 days ago - GlobeNewsWire

GSK to cap out-of-pocket inhaler costs in US

British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United St...

8 days ago - Reuters

Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients

Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, the latest f...

12 days ago - Forbes

AHF Urges Trinidad and Tobago to Sidestep Greedy GSK

LOS ANGELES--(BUSINESS WIRE)-- #AIDS--AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK an...

13 days ago - Business Wire

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

PHILADELPHIA--(BUSINESS WIRE)--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise.

21 days ago - Business Wire

GSK's blood cancer drug meets main goal in late-stage trial; analysts tout comeback

GSK said on Thursday a study showed its experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms worsening, marking a potential comeback for the drug a...

21 days ago - Reuters

WHO says resistance to GSK's HIV drug is growing

The World Health Organization said on Tuesday that data shows resistance to the drug is growing in patients receiving GSK's HIV drug, dolutegravir.

23 days ago - Reuters

GSK's new HIV drug formula could support longer dosing intervals

GSK said on Monday a new formulation of its HIV prevention and treatment drug could potentially be administered at least every four months, an improvement from the previous requirement of dosing every...

24 days ago - Reuters

GSK CEO Emma Walmsley's total pay rises 51% to nearly 13 mln pounds in 2023

GSK CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, thanks to a big jump in performance-related pay, the British drugmaker's annual report showed on Frida...

27 days ago - Reuters

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

4 weeks ago - Market Watch

GSK settles another lawsuit on heartburn drug Zantac in California

GSK agreed to confidentially settle another lawsuit in California that had alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements made by the British drugm...

4 weeks ago - Reuters

GSK's gonorrhoea drug meets primary goal in late-stage trial

British drugmaker GSK said on Monday its oral gonorrhoea drug met its primary goal of non-inferiority in a late-stage trial, compared to an existing combination treatment.

4 weeks ago - Reuters

First Long-Acting Injectable HIV Treatment Works Better Than Daily Pills For Some Patients, GSK Says

British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus's progressi...

5 weeks ago - Forbes

GSK's injectable HIV drug shows promise over daily pills

British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing ch...

5 weeks ago - Reuters

GSK completes acquisition of Aiolos Bio for up to $1.4 bln

GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.

6 weeks ago - Reuters

GSK Exercises Option to License Elsie Biotechnologies' Discovery Platform to Find and Develop Novel Oligonucleotides

SAN DIEGO--(BUSINESS WIRE)--GSK Exercises Option to License Elsie Biotechnologies' Discovery Platform to Find and Develop Novel Oligonucleotides.

6 weeks ago - Business Wire

Hedge fund snaps up stake in Love Island maker ITV

A hedge fund has bought a 5% stake in the U.K.'s largest commercial television broadcaster ITV, as the broadcaster struggles against a slump in the advertising market that has pummeled its share price...

Other symbols: LBTYA
6 weeks ago - Market Watch

Goldman Sachs Says 'GRANOLAS' Stocks Are Set to Enjoy Further Gains

Large-cap European firms with a global footprint and strong balance sheets have outperformed the 'Magnificent Seven' US stocks and are poised for further gains, according to Sharon Bell, senior Europe...

6 weeks ago - Bloomberg Markets and Finance

Nervous About Nvidia, Tesla and the Magnificent 7? Look at Goldman's GRANOLAS.

Some of the biggest European stocks offer a better risk-adjusted return than the Magnificent 7, and that's not their only quality.

6 weeks ago - Barrons

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.

6 weeks ago - Market Watch

GSK's RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

PHILADELPHIA--(BUSINESS WIRE)-- #AREXVY--GSK's RSV vaccine, AREXVY, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk.

7 weeks ago - Business Wire

GSK confidentially settles another Zantac lawsuit in California

GSK said on Thursday it agreed to confidentially settle one more lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end c...

2 months ago - Reuters

GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost

The RSV shot, called Abrysvo, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.

2 months ago - CNBC

GSK lifts long-term outlook following launch of blockbuster vaccine in 2023

GSK on Wednesday lifted its long-term outlook for 2026-2031 as it predicted new drug and vaccine launches will see its annual sales hit £38 billion by the start of the next decade following the blockb...

2 months ago - Market Watch

GSK Lifts Outlook After Sales Boost

GSK said its fourth-quarter sales topped £8 billion, thanks to its best-selling shingles vaccine, and raised its guidance for 2024.

2 months ago - WSJ